In the past week, AMLX stock has gone down by -24.61%, with a monthly gain of 10.88% and a quarterly surge of 134.51%. The volatility ratio for the week is 13.21%, and the volatility levels for the last 30 days are 10.88% for Amylyx Pharmaceuticals Inc. The simple moving average for the past 20 days is -4.86% for AMLX’s stock, with a 22.06% simple moving average for the past 200 days.
Is It Worth Investing in Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Right Now?
Company’s 36-month beta value is -0.73.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 1 as “overweight,” 6 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for AMLX is 43.24M, and currently, short sellers hold a 2.98% ratio of that floaft. The average trading volume of AMLX on November 19, 2024 was 1.38M shares.
AMLX) stock’s latest price update
The stock of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) has increased by 11.34 when compared to last closing price of 4.76.Despite this, the company has seen a loss of -24.61% in its stock price over the last five trading days. seekingalpha.com reported 2024-11-09 that Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX ) Q3 2024 Earnings Call Transcript November 7, 2024 8:00 AM ET Company Participants Lindsey Allen – Head of Investor Relations and Communications Justin Klee – Co-Chief Executive Officer Camille Bedrosian – Chief Medical Officer James Frates – Chief Financial Officer Joshua Cohen – Co-Chief Executive Officer Conference Call Participants Charlie Yang – Bank of America Merrill Lynch Michael DiFiore – Evercore ISI Graig Suvannavejh – Mizuho Securities USA Basma Radwan – Leerink Partners Ananda Ghosh – H.C. Wainwright & Co. Joel Beatty – Robert W.
Analysts’ Opinion of AMLX
BofA Securities, on the other hand, stated in their research note that they expect to see AMLX reach a price target of $10, previously predicting the price at $4.20. The rating they have provided for AMLX stocks is “Buy” according to the report published on October 23rd, 2024.
Mizuho gave a rating of “Neutral” to AMLX, setting the target price at $4 in the report published on March 18th of the current year.
AMLX Trading at 27.04% from the 50-Day Moving Average
After a stumble in the market that brought AMLX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -73.43% of loss for the given period.
Volatility was left at 10.88%, however, over the last 30 days, the volatility rate increased by 13.21%, as shares surge +13.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +110.32% upper at present.
During the last 5 trading sessions, AMLX fell by -24.61%, which changed the moving average for the period of 200-days by -66.41% in comparison to the 20-day moving average, which settled at $5.57. In addition, Amylyx Pharmaceuticals Inc saw -63.99% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at AMLX starting from Klee Justin B., who sale 18,589 shares at the price of $3.20 back on Sep 30 ’24. After this action, Klee Justin B. now owns 3,120,569 shares of Amylyx Pharmaceuticals Inc, valued at $59,429 using the latest closing price.
Cohen Joshua B, the Co-Chief Executive Officer of Amylyx Pharmaceuticals Inc, sale 18,589 shares at $3.20 during a trade that took place back on Sep 30 ’24, which means that Cohen Joshua B is holding 3,220,569 shares at $59,414 based on the most recent closing price.
Stock Fundamentals for AMLX
Current profitability levels for the company are sitting at:
- -1.27 for the present operating margin
- 0.32 for the gross margin
The net margin for Amylyx Pharmaceuticals Inc stands at -1.32. The total capital return value is set at -1.27. Equity return is now at value -84.43, with -72.35 for asset returns.
Currently, EBITDA for the company is 39.89 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.5. The receivables turnover for the company is 113.51for trailing twelve months and the total asset turnover is 0.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.55.
Conclusion
In a nutshell, Amylyx Pharmaceuticals Inc (AMLX) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
